CytoMed Therapeutics Ltd Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Reporting Calendar
| Event | Expected Date |
|---|---|
| Full-Year 2026 Financial Results and Form 20-F Filing | 31 Mar 2027 |
Monitoring Framework
Key Performance Indicators
CTM-N2D Phase I Clinical Trial (ANGELICA Trial) Patient Enrollment Quarterly6.0Target: Complete Phase I dose-escalation trial
Cash and Bank Balances (USD) Semi-Annually1.6MTarget: Secure additional non-dilutive or equity financing to extend runway
Annual Research and Development Expenses (USD) Annually1.7MTarget: Manage clinical trial costs within budget
Watch Items
- Investigational New Drug (IND) Application for CTM-GDT in MalaysiaTrigger: Submission to Malaysian authorities (National Pharmaceutical Regulatory Agency)Action: Monitor regulatory feedback and transition CTM-GDT into a multi-site Phase I clinical trial in collaboration with Universiti Malaya.
- Going Concern and Capital RunwayTrigger: Cash reserves falling below 12 months of operating expensesAction: Utilize the active At-The-Market (ATM) equity program (up to $4.3M USD) or execute asset monetization of owned real estate properties.
- Dose Level 2 Initiation for ANGELICA TrialTrigger: First patient dosed at Dose Level 2Action: Track safety, dose-limiting toxicities, and efficacy signals of CTM-N2D in patients with advanced solid tumors.
Research as of 20 Jun 2026